Boehringer Ingelheim has launched a cat-specific presentation of Metacam Injection combined with a new indication which permits the company's existing oral suspension (0.5mg/ml meloxicam) to be used for up to four follow-on days.

The company says this will give veterinary surgeons increased flexibility for managing feline post-operative pain, and that the new Metacam 2mg/ml Injection helps accurate dosing. Used at the recommended dose rate of 0.2mg/kg, the injection can be followed by Metacam 0.5mg/ml Oral Suspension to provide up to five days of analgesia following surgical procedures in cats. The licensed claims for Metacam 5mg/ml Injection for dogs and cats have not changed.

Boehringer added that Metacam is now the only brand which enables vets to offer their feline patients several days of post-operative analgesia, as well as being approved for long-term use for chronic musculoskeletal disease.

Claire Fowler, Boehringer Ingelheim's companion animal marketing manager, says that the new presentation and indication are significant developments in feline post-operative pain management: "Around half of all dogs undergoing surgery receive an injectable NSAID followed by a follow-on oral NSAID. In cats this figure is around 22%, yet there is no evidence to suggest that pain perception in cats should be any different to that of dogs". 


Whilst you're here, take a moment to see our latest job opportunities for vets.